Trial Profile
Compare the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-Dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 13 Jan 2011 Results published in Vaccine.
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
- 13 Apr 2007 Results have been reported.